Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) had its price objective increased by equities researchers at LADENBURG THALM/SH SH from $24.00 to $25.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. LADENBURG THALM/SH SH's price target indicates a potential upside of 380.77% from the company's previous close.
Other analysts have also issued reports about the company. StockNews.com raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, January 24th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Tuesday.
Get Our Latest Analysis on CAPR
Capricor Therapeutics Stock Down 4.4 %
Shares of CAPR traded down $0.24 during midday trading on Tuesday, hitting $5.20. The company's stock had a trading volume of 667,272 shares, compared to its average volume of 298,965. Capricor Therapeutics has a one year low of $2.68 and a one year high of $8.22. The company's fifty day simple moving average is $5.93 and its two-hundred day simple moving average is $4.61. The stock has a market capitalization of $163.80 million, a price-to-earnings ratio of -5.98 and a beta of 4.06.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.21. The company had revenue of $12.09 million for the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. On average, research analysts predict that Capricor Therapeutics will post -0.83 earnings per share for the current year.
Institutional Trading of Capricor Therapeutics
A number of large investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the first quarter valued at $40,000. Jump Financial LLC bought a new stake in Capricor Therapeutics during the fourth quarter valued at $258,000. Citigroup Inc. bought a new stake in Capricor Therapeutics during the third quarter valued at $211,000. Finally, Vanguard Group Inc. boosted its stake in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after buying an additional 200,499 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
